Journal of Clinical Oncology, Vol 13, 1623-1631, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer

E de Campos, J Radford, W Steward, R Milroy, M Dougal, R Swindell, N Testa and N Thatcher
Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom.

PURPOSE: Recombinant human erythropoietin (r-Hu-EPO) is known to be effective in untreated cancer patients. Here we assess the possibility that r-Hu-EPO may also prevent or reduce anemia in patients who receive cytotoxic chemotherapy. METHODS: Thirty-six patients with small-cell lung carcinoma (SCLC) were enrolled onto a three-arm, randomized trial to investigate the effect of r-Hu-EPO on hemoglobin (Hb) levels and RBC and platelet (Plt) transfusions during chemotherapy. Bone marrow progenitors were studied before and after treatment. Two groups of patients received r-Hu-EPO at a dose of either 150 IU/kg (group 150) or 300 IU/kg (group 300) three times per week for the duration of chemotherapy. A control group did not receive r-Hu-EPO (group O). A maximum of six cycles of a chemotherapy regimen that consisted of vincristine, ifosfamide, carboplatin, and etoposide (VICE) were given to all patients. Hematologic parameters were measured weekly, and RBC or Plt transfusions were given for Hb levels less than 9 g/dL and Plt counts less than 20 x 10(9)/L. RESULTS: Hb levels decreased in all patients, but onset of anemia was delayed in groups that received r-Hu- EPO (P = .002). A total of 116 U RBC were transfused in group 0, 54 in group 150, and 52 in group 300 (P = .017). In addition, there was a nonsignificant trend toward higher Plt counts and fewer Plt transfusions in patients who received r-Hu-EPO. CONCLUSION: r-Hu-EPO at a dose of either 150 or 300 IU/kg three times weekly delays the onset of anemia and reduces RBC transfusion requirements in patients who undergo intensive chemotherapy for SCLC. A possible effect of r-Hu-EPO on platelet numbers deserves further study.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Glaspy, L. Degos, M. Dicato, and G. D. Demetri Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials Oncologist, April 1, 2002; 7(2): 126 - 135. [Abstract] [Full Text] [PDF]

				T. J. Littlewood, E. Bajetta, J. W.R. Nortier, E. Vercammen, and B. Rapoport Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Oncol., June 1, 2001; 19(11): 2865 - 2874. [Abstract] [Full Text] [PDF]

				T. G Davidson Anemia and fatigue in cancer patients Journal of Oncology Pharmacy Practice, December 1, 1998; 4(4_suppl): S5 - S11. [Abstract] [PDF]

				T. G Davidson Recombinant human erythropoietin (rhEPO) in the management of anemia and fatigue associated with solid tumors Journal of Oncology Pharmacy Practice, December 1, 1998; 4(4_suppl): S18 - S24. [Abstract] [PDF]

				D. S. Alberts and R. T. Dorr New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors Oncologist, February 1, 1998; 3(1): 15 - 34. [Abstract] [Full Text]

				M. Cazzola, F. Mercuriali, and C. Brugnara Use of Recombinant Human Erythropoietin Outside the Setting of Uremia Blood, June 15, 1997; 89(12): 4248 - 4267. [Full Text] [PDF]